MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.

J Transl Med · 2016 · PMC4869295 · PMID 27184134

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Nevertheless, MET CN gain showed a trend as an independent unfavourable marker in patients who presented with de novo mBC, which might be considered as a surrogate for an adverse effect of MET CN aberrations in the present clinical context.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.